Targeted Talks: Recent Episodes
Targeted Talks
Targeted Oncology brings you Targeted Talks, a monthly podcast featuring discussions with academic and community oncologists surrounding advancements in cancer research and best practices for patient management.
In part 2 of this conversation, oncologists discuss how they help both patients and trainees navigate an overwhelming volume of medical information. The speakers describe encouraging patients to consult reliable resources like NCCN's patient site rather than turning solely to AI chatbots, while also acknowledging patients will inevitably seek outside information and clarification from family.
For fellows, the panel emphasizes using training time intentionally: reading about patients in depth before appointments, focusing on core algorithms during subspecialty rotations, and building relationships with mentors who can be lifelong resources. Dr Demel highlights curated tools like condensed literature summaries and topic-specific podcasts as more efficient than reading full journals, especially given the explosive growth in oncology trials and publications over the past two decades alongside rising retraction rates. Dr Mehta describes using voice-based AI during a daily commute to get updated on relevant papers, a habit some fellows have since adopted.
The discussion turns to varying attitudes toward AI among colleagues, with speakers describing a spectrum from enthusiastic adopters to skeptics wary of hallucinations. Dr Ji stresses recognizing "good enough" knowledge limits, using AI to stay current on standard-of-care changes and practice-changing trials, while emphasizing that human collaboration and communication remain essential when navigating complex cases beyond one's expertise.
The conversation closes with reflections on reading outside one's specialty to address patients' broader health needs, including medication interactions and comorbidities. Panelists describe current AI use as still in its "infancy," with promising applications emerging in patient monitoring, wearable data, and predictive analytics. Take-home messages include "cautious optimism" about AI's power and a prediction that oncologists who learn to use AI effectively will have a distinct advantage in the field's future.
In this episode of Treating Together, host Dr Pallav Mehta sits down with Dr Kurt Demel and Dr Yan Ji, 2 community-based medical oncologists practicing in the Twin Cities, to tackle a problem every oncologist feels but few have named clearly: information overload.
The conversation opens with a deceptively simple question: When does learning become overload? The group traces the line from the genuine joy of working in a constantly evolving field to the point where the sheer volume of trial data, survival end points, and subgroup analyses makes it hard to land on a clear recommendation for the patient in the room. Dr Ji offers a memorable framing for this: the "memory battery" that drains over the course of a clinic day, leaving even thorough research feeling unresolved when conflicting trials point in different directions.
From there, the discussion moves into how oncologists actually cope by leaning on colleagues through email threads and group chats, the growing divide between generalist and subspecialist practice, and how increasingly informed patients (armed with their own ChatGPT printouts) are reshaping the visit itself. The back half of the episode digs into AI's expanding role in oncology: ambient note-taking, evidence-summarization tools like OpenEvidence, and AI-assisted clinical trial matching, alongside real concerns about hallucinated summaries, erosion of foundational clinical reasoning in trainees, and the risk of applying trial data to patients who don't resemble the trial population. The episode closes on a note of cautious optimism—AI as a tool to clear away noise, not a replacement for the clinical judgment and human connection that the panel agrees remains the real value an oncologist brings to a patient.
In this episode, managing editor Sabrina Serani sits down with 3 experts at the intersection of oncology pharmacy, health informatics, and drug distribution to unpack the 505(b)(2) regulatory pathway and what it means for cancer centers navigating today's complex drug landscape.
Guests:
- Jessica White, PharmD, Vice President, Specialty Programs & Portfolio Management at McKesson
- Derek Burns, PharmD, Senior Director, MID Solutions at McKesson
- Nick Brady, Director, Health Informatics at Central Arkansas Radiation Therapy Institute (CARTI)
What We Cover:
The 505(b)(2) Pathway Explained — Jessica breaks down how the 505(b)(2) new drug application differs from a traditional NDA, allowing drug developers to build on existing FDA-recognized data through bridging studies. The result: faster approvals, lower development costs, and drugs that improve on — rather than simply duplicate — what's already on the market.
Why Oncology, Why Now — Nick explains how 505(b)(2) drugs address a critical pain point in oncology practice: supply disruption. When reference products go on allocation or become unavailable, these drugs provide a meaningful alternative — and in some cases, meaningful clinical improvements like reduced toxicity, modified dosage forms, or improved adherence.
The Real Friction Points — Derek identifies where practices actually get stuck: not at the clinical level, but in operations. Launching without a brand name, missing J-codes, absent ASP data, and gaps in the CMS NDC crosswalk all create hesitation in revenue cycle teams. The underlying problem, he argues, is almost never resistance to innovation — it's undefined coverage, coding, and workflow clarity at launch.
Who Needs to Be at the Table — Nick walks through Carti's internal adoption process, emphasizing that economic evaluation must run in parallel with patient impact assessment. A cross-functional team — pre-certification, pharmacy (both infusion and dispensing), billing and coding, and claims monitoring — needs to move together, with a single source of truth so that no one on the front lines is working from conflicting information.
Practical Strategies for Adoption — The group converges on two key approaches: front-load organizational alignment before the first dose is given, and start narrow with a defined pilot population before any broad rollout. Derek and Jessica also stress the value of a designated practice champion who can coordinate across departments and pressure-test coverage and economics in advance.
The Patient at the Center — When everything is working, patients experience seamless transitions between products, fewer delays, and — in some cases — therapies that are easier to tolerate and stay on. The panel emphasizes that a well-integrated 505(b)(2) strategy should be invisible to the patient while delivering real downstream clinical and economic benefit.
Safety Considerations — Derek underscores that practices managing multiple agents within the same drug category face real risks around dispensing, billing, and administration if labeling and workflows aren't airtight. Jessica notes that the industry is correcting course, with more manufacturers now launching 505(b)(2) products with distinct brand names — reducing the risk of misidentification.
Where the Pipeline Is Headed — Jessica closes with a look at the road ahead: more branded manufacturers entering the 505(b)(2) space, a growing pipeline from traditional generic manufacturers focused on oncology, and a strategic emphasis on supply redundancy and clinical improvements for older, well-established agents that have experienced drug shortages.
Key Takeaways:
- Treat 505(b)(2) drugs as an operational, clinical, and financial tool, not just an economic play.
- Every oncology practice will likely carry multiple agents in the same category; managing that inventory safely is non-negotiable.
- If you've seen one 505(b)(2), you've seen one. Ask what's actually different, what the evidence supports, and how it fits your patients.
- "Not yet" is more accurate than "never": even practices not ready to adopt should be educating staff now.
Ahead of the 2026 ASCO Annual Meeting, Sabrina Serani, managing editor of Targeted Oncology, previews the late-breaking abstracts most likely to influence clinical practice across breast, colorectal, prostate, and lung cancer, as well as in metastatic uveal melanoma, a disease that has gone without an effective systemic therapy for decades. From VIKTORIA-1 in PIK3CA-mutant metastatic breast cancer to BREAKWATER's first look at overall survival in BRAF V600E-mutant colorectal cancer, this episode breaks down the science, the clinical context, and the questions that full data will need to answer.
In this episode of the Treating Together podcast, host Pallav Mehta, MD, medical oncologist at MD Anderson Cancer Center at Cooper University Health Care and medical director of Reimagine Care, speaks with E. Anders (Andy) Kolb, MD, president and chief executive officer of Blood Cancer United (formerly The Leukemia & Lymphoma Society; LLS). Together, they unpack the major forces shaping change in pediatric hematologic malignancies—from biology to treatment/care delivery and advocacy—and how they converge to rapidly translate research into practice.
Key Discussion PointsThe conversation explores the momentum in pediatric blood cancer research and treatment, highlighting how genomics, clinical trials, and large-scale initiatives are reshaping care. Highlights include:
- Distinct Biology Driving Different Treatment Needs: Advances in genomic profiling reveal that pediatric leukemias are biologically distinct from adult disease, with more structural mutations (eg, translocations) rather than targetable point mutations—limiting applicability of many adult therapies.
- Barriers to Progress in Pediatric Myeloid Malignancies: Despite advances, progress in pediatric myeloid malignancies lags behind due to fewer actionable targets and limited drug development incentives.
- Clinical Trials as the Backbone of Care: Unlike adult oncology, trial participation is deeply embedded in pediatric care, with high enrollment rates driven by limited approved therapies, strong cooperative group infrastructure, and family motivation.
- Measuring Impact Beyond Survival: Beyond traditional end points like overall survival, the concept of life years saved highlights the long-term impact of curing children and informs research prioritization.
- Survivorship as a Research Driver: Long-term treatment effects (eg, infertility, organ damage) shape modern trial design, with increasing efforts to reduce toxicity and replace chemotherapy with targeted or immune-based therapies.
- Global Efforts Accelerating Progress: Initiatives like Blood Cancer United’s Dare to Dream are advancing research, access, and advocacy for high-risk pediatric patients.
In this episode of Treating Together, host Marc Braunstein, MD, PhD, associate professor of medicine at the NYU Perlmutter Cancer Center, sits down with Adam Kittai, MD, associate professor and director of the CLL and Lymphoma programs at NYU Perlmutter Cancer Center, for a deep dive into the rapidly evolving frontline treatment landscape in chronic lymphocytic leukemia (CLL). As chemotherapy continues to give way to targeted and time-limited therapies, clinicians face an increasingly complex array of choices, each influenced by disease biology, patient preferences, and emerging clinical trial data.
Key Discussion Points
The episode focuses on the evolving frontline management of CLL and how clinicians can individualize therapy in an era of expanding options. Highlights include:
- Patient Evaluation and Diagnosis Considerations: Beyond traditional risk factors such as TP53 mutation and IGHV status, importance is also being placed on patient preference, comorbidities, and treatment goals (eg, time-limited vs continuous therapy) to guide treatment decisions.
- Therapy Selection and Sequencing Strategy: Dr Kittai offers his view on sequencing decisions in the front line: given the lack of robust comparative data, current evidence supports prioritizing the most appropriate upfront regimen rather than relying on uncertain sequencing strategies across agents.
- Insights From the AMPLIFY Trial (NCT03836261): With the recent February 2026 FDA approvalof acalabrutinib (Calquence) plus venetoclax (Venclexta) in the front line, the discussion highlights progression-free survival (PFS) benefits seen in the AMPLIFY trial and favorable safety of the doublet.
- The Growing Role of Minimal Residual Disease (MRD): The discussion briefly pivots to the use of MRD testing in the clinic today, including data from trials like GLOW (NCT03462719) and FLAIR (EudraCT: 2013-001944-76), and its potential to guide treatment duration.
- Emerging Therapeutic Strategies in the Pipeline: The conversation looks to the future of CLL care, including Bruton tyrosine kinase (BTK) degraders, next-generation BCL-2 inhibitors, and novel combinations currently under investigation.
- Managing Richter’s Transformation: Dr Kittai covers evolving combination approaches for this aggressive cancer that aim to target both CLL and lymphoma biology, moving beyond chemoimmunotherapy.
In this episode of Targeted Oncology’s Treating Together podcast, Dr Pallav Mehta sits down with Dr Sanjay Juneja, aka The Onc Doc, a medical oncologist known for his social media presence and his work in medical informatics. The duo explores how the landscape of cancer care is shifting from a "paucity of information" to a challenge of "information overload," and how technology can bridge the gap between clinical expertise and patient understanding.
The Rise of the "Social" Oncologist
Dr Juneja shares his transition from creating "theatrical" social media content to using his platform for democratizing medical information.
- Myth Busting: He initially focused on debunking cancer myths and explaining complex topics like vaccines and blood clots in digestible ways.
- Broad Reach: With millions of downloads across 110 countries, his content reaches a primary demographic of 40- to 45-year-olds who are often navigating cancer journeys for themselves or loved ones.
- The Power of Evergreen Content: Dr Juneja advocates for using video as a "digital smart phrase" to reinforce complex explanations (like receptor status or chemotherapy side effects) that patients may not fully absorb during a brief 15-minute clinic visit.
AI and the Evolution of Expertise
The conversation highlights how AI is redefining what it means to be a medical expert. Pattern Recognition: Modern expertise is moving away from purely anecdotal experience toward the ability to leverage massive volumes of aggregate data and longitudinal outcomes through AI.
* Personalized Navigation: Large language models (LLMs) are beginning to integrate with medical records, potentially acting as "agents" that help patients filter online information to see if it specifically applies to their unique diagnosis.
* Digital Twins and Avatars*: For physicians uncomfortable on camera, Dr Juneja discusses the potential for AI-generated avatars to deliver standardized, high-quality medical explanations to patients.
Bridging the Gaps in Care
Both doctors emphasize the limitations of the current "point-to-point" interaction model and the need for continuous monitoring. Virtual Care Benefits: Remote care and wearable devices allow for the tracking of subtle, grade 1 toxicities that might otherwise be missed between monthly visits.
* The Emotional Quotient: While AI handles data, Dr Juneja argues that "emotion" and "quantified suffering" remain the unique domain of the human physician, helping patients navigate the regret and "gut feelings" associated with difficult treatment decisions.
* Trusting Intuition*: Dr Juneja concludes by encouraging patients to act on their gut feelings and ask questions without fear of offending providers, noting that this is the best hedge against future regret.
Dr Gabriel Mannis from Stanford University and Dr Gail Roboz from Weill Cornell Medicine discussed the evolving treatment landscape for relapsed/refractory NPM1-mutant acute myeloid leukemia (AML). The conversation highlighted the dramatic transformation of relapsed/refractory AML management from a space where "drugs went to die" to one with multiple targeted therapeutic options.
Dr Roboz emphasized the importance of comprehensive mutational reassessment at relapse, as co-mutation profiles can change from initial diagnosis. She distinguished between mutational profiling for treatment selection versus minimal residual disease (MRD) monitoring, noting that NPM1 was previously considered undruggable but now has two FDA-approved menin inhibitors: revumenib and ziftomenib.
In this episode of the Treating Together podcast, host Dr Pallav Mehta, medical oncologist at MD Anderson Cancer Center at Cooper, assistant professor of medicine at Cooper Medical School, and medical director of Reimagine Care,
sits down with Jorge Garcia, PharmD, founder of Patagonia Healthcare, for an in-depth conversation about the rapidly evolving landscape of advanced cancer therapies, from CAR-T cells and bispecific antibodies to gene therapies.
Together, they explore what makes these treatments fundamentally different from traditional chemotherapy and immunotherapy, and why the systems built to deliver them must evolve just as quickly. The discussion covers the operational, financial, and clinical challenges facing health systems looking to bring bispecific therapies into community and outpatient settings — including reimbursement models, toxicity monitoring, caregiver education, and the critical role of oncology pharmacists. Dr Mehta and Dr Garcia also look ahead to the growing promise of technology, AI, and virtual care in enabling safer patient monitoring outside of hospital walls, and share their vision for a future where more patients can receive these transformative treatments closer to home.
Whether you're a clinician, administrator, pharmacist, or healthcare innovator, this conversation offers a grounded and forward-looking perspective on what it will take to make cutting-edge cancer care accessible to all patients—not just those near major academic centers.
In this minisode, we break down the latest update to ASCO's living guideline for stage IV non–small cell lung cancer (NSCLC) without driver mutations — and what it means for clinicians on the front lines of care.
We're drawing on a conversation with Dr. Joshua Reuss, thoracic medical oncologist at Georgetown University and co-chair of ASCO's Living Guidance Committee, who helped explain the key changes, the remaining uncertainties, and where the field is heading.
What changed — and why now? This was a scheduled comprehensive review, not triggered by a single trial or approval. The committee revisited existing recommendations and incorporated emerging data, even when it didn't clear the bar for a formal change in recommendation level.
Why this guideline is especially complex Unlike driver-positive NSCLC, where a mutation points clearly to a targeted therapy, the driver mutation–negative guideline must address a wide, heterogeneous population — split by histology (nonsquamous vs. squamous) and three PD-L1 tiers, resulting in six distinct patient subsets, each with its own evidence base.
Molecular testing moves to the top A key structural change: comprehensive molecular testing is now front and center in the guideline, reinforcing that confirming the absence of a driver mutation is just as critical as finding one. Starting immunotherapy before results return can create serious problems — if a driver mutation surfaces later, switching to targeted therapy may carry significant toxicity risks.
New in the toolkit: Teliso-V Telisotuzumab vedotin (Teliso-V), a MET-targeted antibody-drug conjugate, has been added to the guideline following its accelerated FDA approval for patients with high MET protein overexpression. It joins trastuzumab deruxtecan (T-DXd) in the subsequent-line ADC space — and its inclusion further underscores the need for thorough molecular and protein expression testing.
What we still don't know The honest answer to "which frontline regimen is best for my patient?" is: we don't know yet. Ongoing trials like INSIGNA are tackling whether chemo is necessary in high PD-L1 expressers. Co-mutations like STK11 and KEAP1 are being explored as biomarkers for dual checkpoint blockade strategies, though a recent prospective study (NIPPON) added caution — increased toxicity without a clear efficacy signal.
One to watch: ivonescimab This bispecific antibody co-targeting PD-1 and VEGF is generating buzz, with data from China suggesting it may outperform pembrolizumab alone. Dr. Reuss calls it potentially practice-changing — if the global data hold up.
The takeaway The guideline won't hand you one answer. It's designed to give clinicians the evidence they need to make the best decision for the individual patient in front of them.
🔗 Full guideline: ascopubs.org/doi/10.1200/JCO-25-02825
In this episode of Treating Together, host Pallav Mehta, MD, medical oncologist and director of Integrative Oncology at Cooper University Health Care and medical director of Reimagine Care, is joined by Debra Patt, MD, PhD, MBA, oncologist and executive vice president at Texas Oncology. Patt also serves as the president of the Community Oncology Alliance (COA). Their discussion focuses on the rapid transformation of community oncology and the growing pressures shaping its future.
Themes and Key Discussion Points
The episode focuses on the central role of community oncology in preserving local, quality care. Highlights include:
- The Evolution of Community Oncology: Drs Mehta and Patt explore how community oncology has changed over the past 2 decades from largely independent practices to consolidated health systems and clinically integrated networks. Financial forces, including the 340B program and broader reimbursement reform, have significantly influenced consolidation trends.
- Policy as a Driving Force: Dr Patt explores how legislation such as the Inflation Reduction Act (IRA) and evolving Centers for Medicare & Medicaid Services (CMS) reimbursement models may impact drug payment, cash flow, and practice viability.
- The Explosion of Targeted and Advanced Therapies: Oncology has entered an era of unprecedented therapeutic expansion. With this progress comes more complexity: longer treatment durations, higher toxicity management demands, and logistical hurdles of administration.
- Digital Transformation and AI Integration: With the accelerating role of digital tools and artificial intelligence (AI) in practice, practices face both opportunity and implementation challenges.
- Workforce and Rural Access Challenges: The conversation addresses mounting physician and nursing shortages, burnout, and the sustainability of rural cancer care, requiring a reimagining of policy, workflow efficiency, and staffing models.
Find a full transcript of the podcast: https://www.targetedonc.com/view/community-oncology-at-a-crossroads-navigating-policy-progress-and-practice
In this episode of Treating Together, host Marc Braunstein, MD, an associate professor of medicine at the Perlmutter Cancer Center, NYU Grossman School of Medicine, is joined by John Burke, MD, from Rocky Mountain Cancer Centers. Both specialists bring their extensive experience in lymphoma and multiple myeloma to a deep-dive discussion on the rapidly evolving treatment landscape of chronic lymphocytic leukemia (CLL).
Key Discussion Points
The episode focuses on the refinement of CLL therapy, moving away from traditional chemoimmunotherapy toward targeted approaches. Highlights include:
- Continuous vs. fixed-duration therapy: A debate on whether patients benefit more from indefinite BTK inhibitor use or time-limited regimens.
- The role of MRD: Exploring how minimal residual disease (MRD) driven duration is becoming a sophisticated option for tailoring treatment.
- Clinical trial updates: Analysis of recent data regarding frontline treatment outcomes and infectious risks.
- Relapsed/refractory strategies: Insights into the recent FDA approval of pirtobrutinib (Jaypirca) for second-line therapy and beyond.
Looking Toward the Future
As the experts look ahead into 2026, they discuss the promising emergence of BTK degraders, which have shown high response rates in heavily pretreated patients and are moving toward potential market availability in the coming years.
This episode of Treating Together, hosted by Chandler Park, MD, featuring guests Benjamin Garmezy, MD, and Manoj Bupathi, MD, centers on the intersection of clinical research and community oncology, specifically within the field of genitourinary (GU) oncology.
Core Themes and Discussion Points
- The Community Oncology Gap: Park highlights a critical statistic: 80% to 85% of patients with cancer are treated in community settings rather than academic centers. The podcast aims to support these community clinicians by translating complex data into practical applications.
- Rapidly Evolving Data: The group discusses the immense challenge of staying current with novel biomarkers, immunotherapy, targeted therapies, and AI in pathology.
- The Burden on Generalists: Garmezy notes that while specialists find it hard to keep up, the "real heroes" are the general community oncologists who see a wide variety of conditions and may only see a handful of GU-specific cases per year.
- Bridging the Research Divide: A primary goal is to narrow the gap between clinical trial findings and real-world clinical practice, ensuring that patients in the community benefit from the latest research.
Find a full transcript of the podcast at https://www.targetedonc.com/view/supporting-community-oncologists-in-a-gu-research-era
Benjamin Garmezy, MD, and Alexander Kenigsberg, MD, discuss strategies for preserving organs in GU cancers in the Treating Together podcast.
Edward S. Kim, MD, MBA, and Neel Shah, MD, discuss advancing lung cancer care and tackling real-world access barriers for community physicians.
In our first episode of Treating Together, Benjamin Garmezy, MD, and Ralph J. Miller Jr, MD, discuss multidisciplinary prostate cancer care.
In this episode of Emerging Experts, Xiaojie Zhang, MD, a hematology/oncology fellow, and Akshat Singhal, PhD, a postdoctoral scholar, both at UC San Diego, shed light on innovative research leveraging deep learning to predict how patients with ER-positive/HER2-negative (ER+/HER2-) breast cancer will respond to palbociclib (Ibrance), a common first-line treatment for this patient population. Their work, fueled by the desire to improve precision oncology, demonstrates the significant potential of artificial intelligence (AI) in guiding cancer care.
In this episode of Targeted Talks, Alfred L. Garfall, MD, discusses the phase 2 BMT CTN 1902 trial (NCT05032820) of idecabtagene vicleucel (ide-cel; Abecma), a study focused on patients with multiple myeloma who had a suboptimal response to first-line therapy, including autologous hematopoietic cell transplant and lenalidomide (Revlimid) maintenance.
David A. Russler-Germain, MD, PhD, physician-scientist at Washington University School of Medicine and Siteman Cancer Center, discusses his path in oncology and the many advancements shaping lymphoma treatment today.
In this episode of Targeted Talks, Aditya Bardia, MD, MPH, FASCO, discusses the recent FDA approval of datopotamab deruxtecan for the treatment of patients with unresectable or metastatic hormone receptor-positive, HER2-negative breast cancer who have received prior systemic therapy.
In this episode of Targeted Talks, Sanjay K. Juneja, MD, hematologist & medical oncologist at Mary Bird Perkins Cancer Center, discusses the exciting advancements of artificial intelligence in 2024, specifically focusing on its transformative impact on early cancer detection.
In this episode of Targeted Talks, Douglas Flora, MD, LSSBB, FACCC, executive medical director of oncology services at St. Elizabeth Healthcare, discusses the transformative impact of artificial intelligence in oncology.
In this episode of Targeted Talks, Seth Wander, MD, PhD, medical oncologist at Massachusetts General Hospital and assistant professor at Harvard Medical School, discusses the clinical importance of ESR1 mutations in hormone receptor-positive metastatic breast cancer and how these mutations influence treatment approaches.
Antonious Hazim, MD, hematology medical oncology fellow at Mayo Clinic, Rochester, Minnesota, shares insights on his journey into oncology, his experiences at the Mayo Clinic, and his ongoing research.
In this episode of Targeted Talks, Virginia Kaklamani, MD, DSc, professor of medicine in the Division of Hematology-Medical Oncology at The University of Texas Health Science Center San Antonio and the leader of the breast cancer program at the Mays Cancer Center, home to UT Health San Antonio MD Anderson Cancer Center, discusses the background, findings, and implications of the phase 3 EMERALD trial.
In this episode of Targeted Talks, James M. Foran, MD, discusses the presentation and diagnosis of blastic plasmacytoid dendritic cell neoplasm.
In this episode of Emerging Experts, Paolo Tarantino, MD, researcher at the European Institute of Oncology, and clinical research fellow at Dana-Farber Cancer Institute, discusses the latest developments in breast cancer research and treatment, focusing on the evolving understanding of HER2-low breast cancer subtypes and the potential advantages of using antibody-drug conjugates.
In this episode of Targeted Talks, Edwin Choy, MD, PhD, discussed the FDA approval of afamitresgene autoleucel for the treatment of patients with advanced synovial sarcoma.
In this episode of Emerging Experts, Yu Fujiwara, shares his journey from Japan to the United States and his path to becoming a specialist in hematology and oncology.
In this episode of Targeted Talks, Omid Hamid, MD, discusses data supporting the use of lifileucel for the treatment of advanced melanoma.
Adam Weiner, MD, discusses his journey toward becoming an oncologist with a focus in urology in this episode of Emerging Experts.
In this episode of Targeted Talks, Binod Dhakal, MD, MS, discusses the recent FDA approval of ciltacabtagene autoleucel for the treatment of relapsed/refractory multiple myeloma.
In this episode of Targeted Talks, Nini Wu, MD, MBA, chief medical and development officer at Cardinal Health, shares her insights on the ever-changing world of technology in the community oncology setting.
In the latest episode of Emerging Experts, Michael LaPelusa, MD, hematology and oncology fellow at MD Anderson Cancer Center, shares his insights, experiences, and passion for cancer research, particularly in the realm of gastrointestinal cancers.
In this episode of Targeted Talks, M. Michele Blackwood, MD, FACS, director of breast surgery, Robert Wood Johnson (RWJ), Barnabas Health, director of women’s oncologic health, RWJ Barnabas Health and Rutgers Cancer Institute, and head of breast surgery, Cooperman Barnabas Medical Center, discusses the current landscape of breast cancer treatment and how personalized medicine with genomic testing is changing the field.
In this episode of Emerging Experts, Nazli Dizman, MD, shares the intricacies of her journey towards becoming an oncologist in the United States.
In this episode, Joshua K. Sabari, MD, discusses the FDA approval of amivantamab plus chemotherapy as a first-line treatment for patients with EGFR exon 20 insertion mutation-positive non-small cell lung cancer.
In this episode of Emerging Experts, Peter Zang, MD, highlights research on baseline CD8 lymph node avidity with 89-Zr-crefmirlimab for the treatment of patients with metastatic renal cell carcinoma and response to immunotherapy.
In season 5, episode 3 of Targeted Talks, Ben Derman, MD, assistant professor of medicine at the University of Chicago Medical Center, dissects the latest advancements in myeloma treatment, focusing on the role of ClonoSeq and minimal residual disease monitoring.
In our 4th episode of Emerging Experts, Minas P. Economides, MD, assistant professor of medicine at NYU Langone Perlmutter Cancer Center, unveils the challenges and opportunities for renal cell carcinoma treatment, focusing on the lack of therapies available in the second-line setting.
In season 5, episode 1 of Targeted Talks, Badrinath Konety, MD, president of the Allina Health Cancer Institute and the chief academic officer for Allina Health, delves into the critical topic of prostate cancer screening, particularly for men within a community setting, and discusses some of the recent advancements in the prostate cancer space.
In season 4, episode 20 of Targeted Talks, Aaron Lisberg, MD, a thoracic medical oncologist at the University of California, Los Angeles, delves into findings from the phase 3 TROPION-Lung01 study of datopotamab deruxtecan for the treatment of patients with advanced or metastatic non–small cell lung cancer.
In our third episode of Emerging Experts, host Jordyn Sava is joined by Matthew Hadfield, DO, a third-year hematology/oncology fellow at Brown University, to discuss his interest and research in immunotherapy toxicities.
In season 4, episode 18 of Targeted Talks, Arvind Dasari, MD, MS, dives into the recent approval of fruquintinib for patients with with metastatic colorectal cancer.
In this episode of Emerging Experts, host Jordyn Sava is joined by Hemali Batra-Sharma, MD, fellow, Hematology/Oncology, University of California San Diego (UCSD) Medical Center, UCSD Health, to discuss insights into her passion for oncology and some of the experiences that have helped to shape her career.
In season 4, episode 16 of Targeted Talks, Susanne G. Warner, MD, hepatobiliary and pancreas surgeon at the Mayo Clinic in Rochester, Minnesota, discusses the importance of tailoring treatments for patients with liver cancer, taking into account the staging of the cancer.
In our first episode of Emerging Experts, Aakash Desai, MD, MPH, discusses his journey through the oncology field by reminiscing on the encouraging guidance of his mentors, personal research goals, and his experiences thus far as an oncologist.
Craig Horbinski, MD, PhD, unpacks the NCCN Clinical Practice Guidelines for central nervous system tumors.
In season 4, episode 9 of Targeted Talks, Kerry Reynolds, MD of Massachusetts General Hospital discusses the occurrence of myocarditis in patients with cancer treated with immune checkpoint inhibitors.
Richard D. Carvajal, MD, discusses mucosal melanoma and treatment options for the disease.
In season 4, episode 3 of Targeted Talks, Pedro Barata, MD, MSc, discusses the present and future of prostate cancer precision medicine.
A talk with Sara A. Hurvitz, MD about advances in the HER2-positive breast cancer space.
In season 4, episode 1 of Targeted Talks, Benjamin L. Schlechter, MD, of Dana-Farber Cancer Institute discuses new studies in gastrointestinal malignancies.
In season 3, episode 10 of Targeted Talks, Nitika Sharma, MD of Cancer Treatment Centers of America, discusses FDA-approved and promising novel therapies for the treatment of small cell lung cancer.
In season 3, episode 10 of Targeted Talks, Nitika Sharma, MD of Cancer Treatment Centers of America Atlanta, discusses FDA-approved and promising novel therapies for the treatment of small cell lung cancer.
In season 3, episode 9 of Targeted Talks, Mohammed Salhab, MD, Chris Fine, MD, FACC, cardiologist at National Jewish Health, have a special discussion about cardiotoxicity from immune checkpoint inhibitor therapy in patients with cancer.
In season 3, episode 8 of Targeted Talks, Christie J. Hilton, DO, discusses treating first- and second-line HER2-positive breast cancer.
In season 3, episode 7 of Targeted Talks, John Nakayama, MD, a gynecologic oncologist at Allegheny Health Network, discusses updates in the endometrial cancer treatment landscape.
Yazan Samhouri, MD, discusses the exciting new agents for the treatment of non-Hodgkin lymphoma, the clinical trials that support their use, and hopes for the future of treatment.
In season 3, episode 5 of Targeted Talks, Thomas Habermann, MD, discusses the latest advances in the treatment of diffuse large B-cell lymphoma.
In season 3, episode 4 of Targeted Talks, Alexey Danilov, MD, PhD, discusses the shift toward utilizing cellular therapy to treat high-risk patients with chronic lymphocytic leukemia.
In season 3, episode 3 of Targeted Talks, William J. Gradishar, MD, discusses the latest version of the NCCN Clinical Practice Guidelines for managing early-stage breast cancer.
Mark Agulnik, MD, City of Hope Comprehensive Cancer Center joins Targeted Oncology for a discussion about the sarcoma treatment landscape and pending innovations under investigation in clinical trials.
In season 3, episode 1 of Targeted Talks, Michael A. Postow, MD, discusses available targeted agents for BRAF-mutant melanoma and ongoing clinical questions about treating the disease.
In season 2, episode 9 of Targeted Talks, Sandy Srinivas, MD and Nicholas J. Vogelzang, MD, discuss he optimal sequencing of therapies for a specific patient with metastatic castration-resistant prostate cancer.
In season 2, episode 8 of “Targeted Talks,” Thomas Hutson, DO, PharmD, and Rana R. McKay, MD, of UC San Diego Health, discussed the renal cell carcinoma paradigm and challenges to overcome in the future.
In season 2, episode 8 of Targeted Talks, Jeff Yorio, MD, and Douglas Johnson, MD, MSCI, joins us for a talk around recent advances in immunotherapy for melanoma.
In season 2, episode 6 of Targeted Talks, Dr. Michael J. Overman joins us for a special discussion around rare genomic alterations in colorectal cancer.
In season 2, episode 6 of Targeted Talks, Alexander B. Olawaiye, MD leads a discussion with Haider S. Mahdi, MD, about the modern approaches to treating cervical and endometrial cancers.
In season 2, episode 4 of Targeted Talks, Benjamin O. Anderson, MD, FACS, discussed the lessons learned from the COVID-19 pandemic, and preparation for a post-COVID America.
Jason Luke, MD, leads a discussion with Sandip Patel, MD, about the present and future of immunotherapy in cancer.
Cathy Eng, MD and Benjamin Weinberg, MD discuss the gut microbiome and how it impacts young patients with colorectal. They also discuss the potential to use gut microbiome test to inform diagnosis, treatment, and monitoring of patients.
Nagashree Seetharamu, MD and with Luis E. Raez, MD discuss the evolving treatment landscape of EGFR exon 20–mutated lung cancer.
Debra Patt, MD, PhD, MBA, speaks with Alex Spira, MD, PhD, FACP, about the impact of the COVID-19 pandemic on community cancer centers and hospitals in the United States
In season 1, episode 4 of Targeted Talks, Michael Schweizer, MD, associate professor. Clinical Research Division, Fred Hutchinson Cancer Research Center, spoke with fellow oncologist, Winston Tan, MD, medical oncologist and professor of medicine, Mayo Clinic, about the ever-changing treatment landscape for prostate cancer.
In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion with Stephanie Graff, MD, and Gabriel N. Hortobagyi, MD, FACP.
Sarah M. Temkin, MD leads a discussion with Daphne B. Stewart, MD, around targeted therapies in ovarian cancer, whether offered in the academic or community setting.
A discussion on immunotherapy use in non–small cell lung cancer between community physician Jason William, MD, DABR and research physician George R. Simon, MD, FACP, FCCP.